Dysarthria News and Research

RSS

Dangerous weight loss trend triggers Iatrogenic botulism outbreak in Europe

Researchers study documents relevant laboratory and epidemiological data on travel-associated iatrogenic botulism outbreaks in Europe.

11 Jun 2023

Deep brain stimulation as obsessive-compulsive disorder treatment

In a recent study published in the Journal of Neurology, Neurosurgery & Psychiatry, researchers investigated the effectiveness of deep brain stimulation (DBS) against treatment-resistant obsessive-compulsive disorder (OCD).

25 Sep 2022

Study explores experiences of speech and language therapists using voice-assisted technology

JMIR Publications recently published "Speech and Language Practitioners' Experiences of Commercially Available Voice-Assisted Technology: Web-Based Survey Study" in JMIR Rehabilitation and Assistive Technologies which reported the professional experiences of UK speech and language therapists using voice-assisted technology (VAT) (e.g. Alexa, Siri) with their clients to identify the potential applications and barriers to VAT adoption and thereby inform future directions of research.

2 Aug 2022

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

Potential link between SARS-CoV-2 infection and secondary occurrence of anti-NMDAR encephalitis

Scientists explore the link between SARS-CoV-2 infection and anti-NMDAR encephalitis.

1 Nov 2021

Study uncovers rare genetic syndrome caused by mutations in gene SATB1

Advances in DNA sequencing have uncovered a rare syndrome which is caused by variations in the gene SATB1.

28 Jan 2021

Chaperone-mediated autophagy could be a new therapeutic target for spinocerebellar ataxia

A research team from Kumamoto University, Japan has developed an animal model that reproduces motor dysfunction and cerebellar neurodegeneration similar to that in spinocerebellar ataxia (SCA) by inhibiting chaperone-mediated autophagy (CMA) in cerebellar neurons.

23 Sep 2020

Hereditary spastic paraplegia characteristics unveiled

Researchers have detailed the characteristics of a large cohort of patients with hereditary spastic paraplegias.

15 Feb 2016

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

Study explores prevalence of chronic brain damage in retired NFL players

A study published online today in Sports Health: A Multidisciplinary Approach provides a different take on previous information regarding the prevalence of chronic brain damage in retired NFL players.

26 Jun 2014

Communication for people with impaired speech: an interview with Professor Mark Hawley, Professor of Health Services Research, Director of CATCH and lead researcher for VIVOCA

There are many different causes of speech impairment but the one we are particularly interested in is actually the most common cause of speech impediment, which is dysarthria.

5 Feb 2014

Loyola University neuropsychologist find little evidence that chronic traumatic encephalopathy actually exists

The media have widely reported that a debilitating neurological condition called chronic traumatic encephalopathy is a well-established disease in retired athletes who played football and other contact sports.

28 Jan 2014

Deep-brain stimulation effects sustained in dystonia

Improvements in dystonia achieved with deep-brain stimulation are usually sustained for at least 5 years, shows follow up of a randomized trial.

15 Nov 2012

Eisai receives FDA approval for Fycompa to treat partial onset seizures

The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.

23 Oct 2012

Poststroke speech therapy ‘should be reorganized’

Results of the randomized ACT NoW trial show no benefit of "enhanced" over "everyday" communication therapy for patients with dysarthria resulting from stroke.

25 Jul 2012

Poststroke speech therapy ‘should be reorganized’

Results of the randomized ACT NoW trial show no benefit of “enhanced” over “everyday” communication therapy for patients with dysarthria resulting from stroke.

20 Jul 2012

DBS safe and effective for patients with advanced Parkinson's

Researchers from the University of Florida and 14 additional medical centers reported results today in the online version of The Lancet Neurology journal indicating that deep brain stimulation - also known as DBS - is effective at improving motor symptoms and quality of life in patients with advanced Parkinson's disease.

12 Jan 2012

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009